GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

NCT06162715 on ClinicalTrials.gov · last registry update 2026-08-04

A small phase 2/phase 3 — 30 participants, against a typical 60. Due to report 1 January 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Weight loss. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 30 October 2024 — 2 years so far. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P2/P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Vanderbilt University Medical Center
Sponsor type: Other
Enrollment: 30
Started: 2024-10-30
Primary completion: 2027-01-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight loss

Conditions studied

Severe Obesity · Obesity · BMI Greater Than 30

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.